Boundless will host a live webcast and conference call on Tuesday, May 27 at 8:00 am ET to discuss these updates. To access the webcast and slides, please visit Events & Presentations in the Investors ...

BioCryst will present four abstracts at the meeting: Impact of Berotralstat on Quality of Life among Patients with Hereditary ...

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first ha ...

SaveHealth explores the distinctions between brand-name and generic drugs, outlines the financial advantages of generic ...

Summer’s almost here, and that means nuisances: mosquitoes, poison ivy, and visiting relatives. Two cause itching, one causes ...

In the Italian expanded access program (EAP), 22 patients received berotralstat free of charge until commercial availability, ...

For conditions where agents have a relatively narrow therapeutic index, notably epilepsy, financial savings through generic substitution might be offset by increases in patient complications and ...

While most generics are excellent substitutes, patients should consult their healthcare provider in these situations: Narrow therapeutic index drugs (e.g., warfarin, levothyroxine): slight ...